Folie 1 - Boehringer Ingelheim
Folie 1 - Boehringer Ingelheim
Folie 1 - Boehringer Ingelheim
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Annual Press Conference 2012<br />
Business Year 2011
Highlights of the Business Year 2011<br />
Andreas Barner<br />
Chairman of the Board of Managing Directors<br />
Corporate Board Division Pharma Research,<br />
Development and Medicine
“Value through Innovation”<br />
Start of a new growth phase<br />
Annual Press Conference 2012<br />
• Again significant above-market growth<br />
• Above-average investments in R&D<br />
• Successful market placement of<br />
trajenta® for type 2 diabetes<br />
• Advances in future therapeutic areas -<br />
oncology and hepatitis C<br />
• Actions over generations<br />
• Our goal - long-term, organic growth<br />
3
Our businesses 2011<br />
Increase in net sales and operating income<br />
In EUR<br />
Net sales<br />
12,586<br />
million<br />
2010 2011<br />
• +4.6% growth on a euro basis<br />
13,171<br />
million<br />
• +6.2% growth (currency-adjusted)<br />
Operating income<br />
1,896 million 2,272 million<br />
2010 2011<br />
• Increase in operating income<br />
• Return on net sales 17.3% (previous year 15.1%)<br />
Development of R&D expenses<br />
2,453 million +63 million 2,516 million<br />
2010 2011<br />
• R&D expenses in Prescription Medicines<br />
corresponds to 23.5% of its net sales<br />
Annual Press Conference 2012 4
<strong>Boehringer</strong> <strong>Ingelheim</strong> on growth course<br />
Group<br />
• Growth in net sales<br />
• Operating income increased<br />
• Start of a growth phase<br />
Strategic potential<br />
• Growth in new markets<br />
• Biopharmaceuticals - new biological<br />
entities and biosimilars<br />
• Animal Health - focus on animal<br />
vaccines<br />
Core products and new launches<br />
• trajenta®<br />
• pradaxa®<br />
• spiriva®<br />
Development portfolio<br />
• Significant progress with clinical<br />
development portfolio<br />
• Oncology and hepatitis C<br />
• Idiopathic lung fibrosis, asthma<br />
Annual Press Conference 2012 5
Global market performance<br />
Growth exceeds the pharmaceutical market<br />
Global market share Growth in constant EUR (%) – 2011<br />
NOVO NORDISK 1.32%<br />
MYLAN 1.08%<br />
OTSUKA 1.22%<br />
* BOEHRINGER INGELHEIM 1.93%<br />
BRISTOL-MYERS SQB. 1.94%<br />
NOVARTIS 6.02%<br />
LILLY 2.82%<br />
MERCK & CO 4.76%<br />
ABBOTT 3.02%<br />
AMGEN 1.95%<br />
Roche 4.06%<br />
DAIICHI SANKYO + RANBAXY 1.27%<br />
BAYER SCHERING 1.90%<br />
TAKEDA 2.13%<br />
ASTRAZENECA 4.40%<br />
SANOFI 4.52%<br />
GLAXOSMITHKLINE 4.01%<br />
JOHNSON & JOHNSON 3.25%<br />
PFIZER 6.68%<br />
TEVA + RATIOPHARM 2.84%<br />
-3.3<br />
-3.6<br />
-2.5<br />
-0.7<br />
-1.2<br />
Note: This data represents 96% of IMS Global MIDAS sales data.<br />
Annual Press Conference 2012<br />
0.4<br />
1.4<br />
1.3<br />
1.2<br />
2.4<br />
3.1<br />
4.6<br />
5.1<br />
4.6<br />
4.5<br />
7.0<br />
8.2<br />
7.8<br />
9.6<br />
9.5<br />
11.9<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Global market share: 1.93%<br />
6
Businesses and Financial Figures 2011<br />
Hubertus von Baumbach<br />
Corporate Board Division Finance and Animal Health
Challenges in 2011 successfully overcome -<br />
Significant improvement in income<br />
in EUR million<br />
2010 2011 Change<br />
Net sales 12,586 13,171 +4.6%<br />
Operating income 1,896 2,272 +19.8%<br />
Equity ratio 39.9% 40.0%<br />
Financial funds 6,113 7,711 +26.1%<br />
Annual Press Conference 2012<br />
• Growth +6.2% (currency-adjusted)<br />
• Solid financing<br />
• Increase in liquidity<br />
8
Prescription Medicines<br />
Gratifying growth<br />
Net sales in EUR million<br />
Prescription<br />
Medicines<br />
Annual Press Conference 2012<br />
12,586<br />
9,702<br />
13,171<br />
10,096<br />
2010 2011<br />
• Growth of +5.3% (currency-adjusted)<br />
• 77% of Group net sales<br />
• In particular due to pradaxa® and<br />
spiriva®<br />
• Decline in sales of sifrol® after patent<br />
expiry<br />
• Launch of trajenta® in 2011<br />
9
Prescription Medicines – Equal growth of newly launched<br />
and established products<br />
Net sales in EUR million, growth (currency-adjusted)<br />
3,153<br />
Annual Press Conference 2012<br />
1,784<br />
766<br />
629<br />
471<br />
+12.6% +6.6% +10.3 % >100 %<br />
–29.5 %<br />
spiriva® micardis®-family combivent® pradaxa® sifrol®/mirapex®<br />
10
Consumer Health Care<br />
Gratifying growth<br />
Net sales in EUR million<br />
Consumer<br />
Health Care<br />
Annual Press Conference 2012<br />
12,586<br />
1,318<br />
13,171<br />
1,396<br />
2010 2011<br />
• Growth +7.1% (currency-adjusted)<br />
• 11% of Group net sales<br />
• Emerging markets +16.7%<br />
11
Consumer Health Care<br />
Strong growth of international core brands<br />
Net sales in EUR million, growth (currency-adjusted)<br />
Market<br />
position*<br />
180<br />
171<br />
160<br />
buscopan® dulcolax® mucosolvan® pharmaton® bisolvon®<br />
* Source: MAT 09/2011 – IMS OTC Rv+ Q3 2011<br />
Annual Press Conference 2012<br />
#1 #1 #2 #3 #3<br />
137<br />
+41.6 % +10.1% +10.8 % +10.0 %<br />
98<br />
+11.0 %<br />
12
Animal Health<br />
Successful vaccines drive growth<br />
Net sales in EUR million<br />
Animal Health<br />
Annual Press Conference 2012<br />
12,586<br />
921<br />
13,171<br />
976<br />
2010 2011<br />
• Growth +7.8% (currency-adjusted)<br />
• 7% of Group net sales<br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> is growing faster<br />
than the market, retains 6th place<br />
• Swine vaccines main growth driver<br />
13
Animal Health – Successful research network<br />
New animal vaccines give better prevention<br />
Our global research and development sites<br />
• European Centre for Animal Vaccines,<br />
Hanover (Germany)<br />
• St. Joseph (USA)<br />
• Guadalajara (Mexico)<br />
• Asian Veterinary Research and<br />
Development Centre, Shanghai (China)<br />
Annual Press Conference 2012<br />
14
Animal Health<br />
Strong growth of top 5 products<br />
Net sales in EUR million, growth (currency-adjusted)<br />
257<br />
96<br />
57<br />
46 43<br />
+8.4 % +3.0% +32.5% +10.7% +2.7%<br />
ingelvac<br />
circoflex®<br />
metacam® ingelvac prrs® vetmedin® ingelvac mhyo®<br />
Annual Press Conference 2012<br />
15
Industrial Customer Business<br />
Biopharmaceuticals main driver<br />
Net sales in EUR million<br />
Industrial<br />
Customer<br />
Business<br />
Annual Press Conference 2012<br />
12,586<br />
638<br />
13,171<br />
697<br />
2010 2011<br />
• Growth +9.2% (currency-adjusted)<br />
• 5% of Group net sales<br />
• Biopharmaceuticals make up 74% of the<br />
Industrial Customer Business<br />
16
Established Markets<br />
Still highly important for our business<br />
Net sales in EUR million<br />
Global<br />
USA<br />
Japan<br />
Germany<br />
950<br />
1,831<br />
4,820<br />
13,171<br />
• Top 3 countries 58%<br />
• Top 10 countries 76%<br />
• USA, Japan, Germany<br />
− Prescription Medicines<br />
− Consumer Health Care<br />
− Animal Health<br />
− R&D and Operations<br />
− Biopharmaceuticals in USA, Germany<br />
• Number of employees in Top 3 countries<br />
− USA 10,016<br />
− Japan 2,832<br />
− Germany 12,501<br />
Annual Press Conference 2012 17
<strong>Boehringer</strong> <strong>Ingelheim</strong> committed to Germany<br />
• 46% of Group investments - EUR 210 million<br />
thereof EUR 156 million in <strong>Ingelheim</strong> for the expansion of<br />
pradaxa® production (116 new jobs in Operations)<br />
• 50% of total expenditure for R&D<br />
• 12.501 employees in Germany, +333 employees<br />
Annual Press Conference 2012<br />
18
Emerging markets<br />
Dynamic growth and future potential<br />
Growth in net sales in % (currency-adjusted)<br />
Russia<br />
China<br />
South America<br />
MENA<br />
Annual Press Conference 2012<br />
+25.5%<br />
+19.1%<br />
+35.1%<br />
+30.2%<br />
• Russia<br />
High net sales growth due to successful<br />
regionalisation, workforce continues to<br />
grow significantly<br />
• South America<br />
Considerable net sales growth in<br />
Argentina and Colombia<br />
• MENA (Middle East/North Africa)<br />
Establishment of organisation and<br />
expansion of product portfolio especially<br />
in North Africa<br />
19
China<br />
Strong growth and expansion of operating activities<br />
Annual Press Conference 2012<br />
• Net sales growth > +30% essentially due to<br />
mucosolvan®, micardis® and spiriva®<br />
• Large rise in workforce to 2,701 (+31.4%)<br />
• Investment in production facility at Zhangjiang High-Tech<br />
Park, Shanghai<br />
• R&D - participation in global development programmes<br />
for diabetes, oncology and respiratory diseases<br />
• Animal Health - Asian Veterinary Research and<br />
Development Centre, development of vaccines for Asia<br />
20
Profitable growth – Increase in operating income and<br />
profitability<br />
in EUR million<br />
2010 2011 Change<br />
Net sales 12,586 13,171 +4.6%<br />
Operating income 1,896 2,272 +19.8%<br />
Financial income –154 –198 –28.6%<br />
Extraordinary result –594 0<br />
Income before taxes 1,114 2,043 +83.4%<br />
Taxes –226 –567<br />
Net income 888 1,476 +66.2%<br />
Annual Press Conference 2012<br />
• Currency effect on net sales<br />
–1.6%<br />
• Increase in R&D expenditure<br />
to EUR 2,516 million (+2.6%)<br />
• 2010 - extraordinary expense<br />
mainly affected by change in<br />
pension accounting<br />
(BilMoG/one-time effect)<br />
21
Cash flow from operating activities covers investing<br />
activities<br />
Cash flow in EUR million<br />
2010 2011<br />
2,056<br />
2,570<br />
Operating activities<br />
–502<br />
Investing<br />
activities<br />
–466<br />
Financing<br />
activities<br />
1,602<br />
Changes in<br />
financial<br />
funds*<br />
* Without changes in financial funds due to exchange rate movements<br />
Annual Press Conference 2012<br />
• Cash flow from operating activities<br />
EUR 514 million higher than in 2010<br />
• Cash flow from financing activities also<br />
includes withdrawals for shareholders’ tax<br />
payments<br />
• Strong rise in financial funds on an<br />
ongoing basis<br />
22
Sustainable business development over past 10 years<br />
Employees<br />
31,843 34,221 35,529 37,406 38,428 39,800 41,300 41,534 42,224 44,094<br />
in EUR million<br />
2,109 2,215 2,453 2,516<br />
1,900<br />
1,574<br />
R&D 1,304 1,176 1,232 1,360<br />
13,171<br />
12,721 12,586<br />
expenditure<br />
11,595<br />
10,952<br />
10,574<br />
Net sales<br />
Operating<br />
income<br />
7,580<br />
7,382<br />
8,157<br />
9,535<br />
1,082 901 1,372 1,923 2,140 2,100 1,980 2,239 1,896 2,272<br />
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011<br />
Annual Press Conference 2012 23
Outlook 2012<br />
Andreas Barner<br />
Chairman of the Board of Managing Directors<br />
Corporate Board Division Pharma Research,<br />
Development and Medicine
pradaxa® for the prevention of stroke in patients<br />
with atrial fibrillation<br />
• High medical demand<br />
• Improved prevention and treatment of acute<br />
and chronic thromboembolic diseases<br />
• Therapeutic breakthrough - reduced risk of<br />
stroke<br />
Annual Press Conference 2012 25
trajenta® for the treatment of type 2 diabetes<br />
Annual Press Conference 2012<br />
• High medical demand and excellent<br />
growth potential<br />
• No dose adjustment and monitoring<br />
necessary in older patients and patients<br />
with a risk of impaired renal function<br />
• First milestone in successful<br />
partnership with Eli Lilly<br />
• Further potential in the diabetes<br />
development pipeline<br />
26
Our Research and Development<br />
Substances in advanced clinical development<br />
Anticoagulation<br />
Dabigatran etexilate, (pradaxa®)<br />
- Treatment and secondary prevention of VTE Phase III<br />
Type 2 diabetes<br />
Empagliflozin, SGLT-2 inhibitor Phase III<br />
Oncology<br />
Afatinib, irreversible tyrosine kinase inhibitor Phase III<br />
Nintedanib, triple angiokinase inhibitor Phase III<br />
Volasertib, polo-like kinase inhibitor Phase II<br />
Hepatitis C<br />
BI201335, protease inhibitor Phase III<br />
BI207127, polymerase inhibitor Phase II<br />
Respiratory diseases<br />
Nintedanib, antifibrotic kinase inhibitor, IPF Phase III<br />
Tiotropium (LAMA) + Olodaterol (LABA), COPD Phase III<br />
Tiotropium (LAMA) monotherapy, asthma Phase III<br />
Annual Press Conference 2012 27
Cooperation with basic research<br />
Investment in treatments of the future<br />
Annual Press Conference 2012<br />
Academic partnerships<br />
• Stanford University (USA)<br />
• Karolinska Institutet (Sweden)<br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> University Ulm<br />
Biocenter (Germany)<br />
• Johannes Gutenberg-Universität Mainz<br />
(Germany)<br />
• Technische Universität Dresden<br />
(Germany)<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Venture Fund<br />
Institute of Molecular Pathology, Vienna<br />
(Austria)<br />
Institute of Molecular Biology, Mainz<br />
(Germany)<br />
28
Biopharmaceuticals<br />
Biosimilars and NBE development<br />
Annual Press Conference 2012<br />
• Entire biopharmaceutical process chain<br />
covered<br />
• Development service for all clinical phases -<br />
from protein scaffolds to antibodies<br />
• Production of new biological entities (NBE)<br />
and biosimilars<br />
• Technology platforms for contract<br />
manufacturing<br />
29
Our employees<br />
Respect, trust, empathy and passion<br />
Annual Press Conference 2012<br />
• Together we create the future of <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
• Special corporate culture<br />
• Establishing entrepreneurial processes<br />
• Safeguarding innovative capabilities<br />
• Talent management<br />
• Leadership development<br />
• Diversity and inclusion<br />
30
Outlook 2012<br />
Guide our own R&D to success<br />
Launch of drugs in the following areas<br />
• Diabetes<br />
• Oncology<br />
• Hepatitis C<br />
• Idiopathic pulmonary fibrosis<br />
• Asthma<br />
Entering new therapeutic areas<br />
• pradaxa® - new market launches and<br />
enhanced positioning<br />
• trajenta® - new market launches and<br />
enhanced positioning<br />
• Establishment of oncology and hepatitis C<br />
Annual Press Conference 2012<br />
Implement strategy<br />
• Organic growth strategy<br />
• Expansion of biopharmaceuticals, process<br />
development, production of biological entities<br />
• Expansion of Animal Health, focus on vaccines<br />
• Safeguarding sustainable independence<br />
Continuation of growth phase<br />
• Forecast for sound, high single-digit growth<br />
• Maintain high level of investment in R&D<br />
31
Annual Press Conference 2012<br />
Business Year 2011
Change language